Rapid Ketamine Relief Points to Brain Plasticity in Depression
Neuroscientist Lisa Monteggia argues that depression cannot be adequately explained as a serotonin shortage: SSRIs raise serotonin quickly, yet often take weeks to relieve symptoms, while ketamine can produce relief within hours through a different brain system. She says ketamine’s effects point instead to synaptic plasticity—the brain’s capacity to adapt—as a possible driver of antidepressant response, though the drug remains temporary, clinically limited and no replacement for first-line SSRI treatment.
The timing problem with serotonin is hard to ignore
Lisa Monteggia starts with a contradiction in the standard account of antidepressants. SSRIs, including Prozac and Zoloft, increase serotonin quickly. Yet the benefits people seek from them can take weeks to appear.
That gap matters because the familiar story of depression has been that people do not make enough serotonin and that medication corrects the resulting chemical imbalance. Monteggia says many people with depression have normal serotonin levels. The serotonin-shortage explanation, she argues, is therefore not the whole story—and may not be the story at all.
SSRIs remain an essential part of treatment in her account. They help many people, can be life-changing and life-saving, and for some give them “the will to live.” Monteggia is explicit that people taking an SSRI should continue taking it. But the delay between an immediate rise in serotonin and a benefit that arrives weeks later remains unexplained: if treatment were simply replacing a deficient chemical, she says, the effect should be rapid.
Ketamine made that timing mismatch more consequential. In a clinical study that was not designed around depression, depressed people receiving a very low dose of ketamine showed an antidepressant effect within hours. Ketamine does not increase serotonin. It acts on a different neurotransmitter system altogether.
The visual account of starting an SSRI makes the practical problem of delayed response clear. Across seven weeks, a person’s perception of treatment is entangled with a text from an ex, nights of drinking, a promotion, a sibling’s breakup and finally a good weekend that makes the medication seem to be working. A delayed effect unfolds amid the ordinary volatility of life.
Depression is not ordinary sadness
Monteggia distinguishes major depression from sadness, melancholy or the creative expression of grief. Picasso’s blue-period paintings, poetry that moves a reader to tears and songs such as Eric Clapton’s “Tears in Heaven” can convey sorrow. Major depression, she says, is a serious medical condition, particularly when untreated.
It can mean dulled emotion, loss of interest and complete withdrawal. Symptoms vary: for one person depression may affect appetite, for another sleep, concentration or memory. Monteggia says it affects more than 280 million people globally and describes it as a leading cause of disability in the United States, with costs in lost productivity for individuals, families and society.
The variation in symptoms is part of why she resists portraying depression as a single missing substance that must be restored. The question raised by ketamine is not merely whether one drug works faster than another. It is what an antidepressant effect is actually changing.
Ketamine points to adaptation rather than replacement
Ketamine has been studied especially in people who do not respond to SSRIs, including people who may have spent decades depressed without effective treatment. Its rapid effect was surprising because antidepressant relief within hours had not been thought possible.
Unlike SSRIs, ketamine does not work by increasing serotonin. It targets the glutamate system, which Monteggia describes as important for fast communication in the brain. More counterintuitively, it does not activate that system. It blocks it.
Her lab and other groups have found that this interruption can strengthen particular connections in the brain through synaptic plasticity. Monteggia says researchers think that adaptive change is what drives ketamine’s antidepressant effect.
It’s the idea that your brain can adapt, and ketamine is able to tap into that.
That finding reframes treatment in her telling. Ketamine is not correcting a serotonin imbalance or repairing a person who is “broken” because they cannot make an essential transmitter. It is tapping the brain’s capacity to change. The speed of the response also changes what patients and researchers can expect from treatment, particularly for people who have not benefited from SSRIs.
A rapid effect is not a permanent or risk-free one
Ketamine is not a replacement for SSRIs. Monteggia identifies SSRIs as the first-line treatment for depression and says ketamine has been most studied in people who do not respond to them. At high levels ketamine is an anesthetic; at intermediate levels it is used as a party drug. Used incorrectly or at very high doses, it can have adverse effects. “More is better” is not the message, she says, and people interested in ketamine should talk with a healthcare provider.
Its antidepressant effect also wanes. Monteggia compares it to flowers in a vase: ketamine can provide relief for a few days, then the effect fades. Her group has initiated studies asking whether an effect triggered by ketamine can be sustained longer, so that patients would not need another treatment as soon.
Maybe their brain is just sort of stuck, and ketamine allows you to adapt, to change.
Monteggia uses a painting analogy to mark the boundary of that claim. Ketamine is not painting a blank canvas or creating new memories. It may instead “dial in” the intensity of despair. She recounts a description from someone whose SSRIs had failed: before ketamine, depression felt like living in a dark room with no windows and no way out. Treatment did not turn it into a party house; it made the light seem lifted and revealed a door.
The research agenda is to use plasticity more safely and for longer
Monteggia’s interest in ketamine extends beyond the drug itself. If ketamine creates a temporary window in which the brain is more able to adapt, researchers can ask what else might make use of that window. Some are testing whether therapy works better during it, and whether other drugs or brain stimulation might trigger or support similar plasticity.
Her group is also pursuing ways to extend the antidepressant response. The aim is to make treatment safer, help it work for more people and sustain benefit without requiring frequent ketamine treatment.
The broader shift is away from a model in which depression is simply a chemical deficit to be corrected. Monteggia’s account does not dismiss existing treatment; it argues that ketamine has exposed a different possibility: relief may come from helping a brain that is stuck regain its capacity to adapt.